Percent change in gastric emptying half‐time from baseline after... | Download Scientific Diagram
Summary of Clinical Trials for Chronic Constipation | Download Table
Velusetrag - an overview | ScienceDirect Topics
Velusetrag | C25H36N4O5S - PubChem
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Clinical Research Trial Listing ( Gastroparesis ) ( NCT01718938 )
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Current developments in pharmacological therapeutics for chronic constipation - ScienceDirect
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut
Theravance Biopharma :: SEC Filing
velusetrag | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
VELUSETRAG
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Is Alfasigma late reporting EU clinical trials?
VELUSETRAG
Velusetrag (TD-5108) | 5-HT4R Agonist | MedChemExpress
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
Theravance Biopharma :: SEC Filing
Velusetrag - Wikiwand
PDF) Velusetrag for the treatment of chronic constipation
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
PDF) Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study | M. Goldberg -
Prokinetics in Phase II and III stages of development | Download Table
Receptor binding profile of 5-HT 4 agonists for GI disorders, at... | Download Table
